These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism. Robinson DM; Wellington K Am J Cardiovasc Drugs; 2005; 5(5):335-46. PubMed ID: 16156690 [TBL] [Abstract][Full Text] [Related]
8. The safety of fondaparinux for the prevention and treatment of venous thromboembolism. Turpie AG Expert Opin Drug Saf; 2005 Jul; 4(4):707-21. PubMed ID: 16011449 [TBL] [Abstract][Full Text] [Related]
9. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis. Bauer KA Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma. Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002 [TBL] [Abstract][Full Text] [Related]
11. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487 [TBL] [Abstract][Full Text] [Related]
12. Fondaparinux sodium: a selective inhibitor of factor Xa. Bauer KA Am J Health Syst Pharm; 2001 Nov; 58 Suppl 2():S14-7. PubMed ID: 11715834 [TBL] [Abstract][Full Text] [Related]
14. [Preclinical and clinical data of the synthetic Xa inhibitor fondaparinux (Arixtra(®))]. Suzuki I; Ozeki Y Nihon Yakurigaku Zasshi; 2012 Mar; 139(3):117-26. PubMed ID: 22451467 [No Abstract] [Full Text] [Related]
15. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery. Tran AH; Lee G Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815 [TBL] [Abstract][Full Text] [Related]
16. [Fondaparinux: the present and the future]. Garcia Hejl C; Garcia C; Thefenne-Astier H; Servonnet A; Samson T; Foissaud V Pathol Biol (Paris); 2008 Mar; 56(2):97-103. PubMed ID: 18178332 [TBL] [Abstract][Full Text] [Related]
17. Setting a standard for venous thromboembolism prophylaxis. Turpie AG Am J Health Syst Pharm; 2001 Nov; 58 Suppl 2():S18-23. PubMed ID: 11715835 [TBL] [Abstract][Full Text] [Related]
18. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy. Turpie AG Expert Opin Pharmacother; 2004 Jun; 5(6):1373-84. PubMed ID: 15163281 [TBL] [Abstract][Full Text] [Related]
19. SAfety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: a pilot study. Cohen A; Stellbrink C; Le Heuzey JY; Faber T; Aliot E; Banik N; Kropff S; Omran H; Arch Cardiovasc Dis; 2015 Feb; 108(2):122-31. PubMed ID: 25684570 [TBL] [Abstract][Full Text] [Related]
20. PK evaluation of fondaparinux sodium for the treatment of thrombosis. Delavenne X; Frappé P; Zufferey P; Mismetti P; Laporte S; Bertoletti L Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):269-77. PubMed ID: 24359588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]